Pub Date : 2026-02-02DOI: 10.1016/j.ejvs.2026.01.053
Pablo Marques de Marino, Drosos Kotelis, Alexander Gombert, Tilo Kölbel, Karin Pfister, Philipp Geisbüsch, Martin Austermann, Johannes Kalder, Martin Czerny, Eric L Verhoeven, Nikolaos Tsilimparis
Objective: To report the early results of a physician initiated clinical trial evaluating the safety and performance of the BeGraft Stent Graft (Bentley InnoMed, Hechingen, Germany) in fenestrated endovascular aneurysm repair (FEVAR).
Methods: This prospective, multicentre, single arm, physician initiated trial enrolled patients undergoing FEVAR for complex aortic aneurysms between March 2021 and September 2023 in nine high volume German centres. The BeGraft Stent Graft was used outside its initial intention for use as a bridging stent graft (BSG) for FEVAR. Primary endpoints were technical success, BSG patency, and absence of procedure related complications and BSG related endoleaks at 12 months.
Results: One hundred and three patients were prospectively enrolled. Three hundred and fifty BSGs were implanted as investigational devices and included in the analysis. Technical success was 98.3%. Two BSG occlusions were reported in the first 12 months. Primary patency at 12 months was 99.3%. The absence of procedure related complications was 88%. Freedom from BSG related endoleaks at 12 months was 99.6%. Freedom from BSG related re-interventions was 97%. Two device deficiencies occurred in two patients: one disconnection between the BSG and the balloon before deployment and one fracture of the BSG at one year. No migration > 10 mm of the BSG was recorded during the trial period.
Conclusion: This study shows favourable short term outcomes of the BeGraft Stent Graft as a BSG in FEVAR with good primary patency and low rates of BSG related complications.
{"title":"Prospective, Multicentre Physician Initiated Trial Investigating the BeGraft Stent Graft as Bridging Stent in Fenestrated Endovascular Aneurysm Repair for Complex Aortic Aneurysms.","authors":"Pablo Marques de Marino, Drosos Kotelis, Alexander Gombert, Tilo Kölbel, Karin Pfister, Philipp Geisbüsch, Martin Austermann, Johannes Kalder, Martin Czerny, Eric L Verhoeven, Nikolaos Tsilimparis","doi":"10.1016/j.ejvs.2026.01.053","DOIUrl":"https://doi.org/10.1016/j.ejvs.2026.01.053","url":null,"abstract":"<p><strong>Objective: </strong>To report the early results of a physician initiated clinical trial evaluating the safety and performance of the BeGraft Stent Graft (Bentley InnoMed, Hechingen, Germany) in fenestrated endovascular aneurysm repair (FEVAR).</p><p><strong>Methods: </strong>This prospective, multicentre, single arm, physician initiated trial enrolled patients undergoing FEVAR for complex aortic aneurysms between March 2021 and September 2023 in nine high volume German centres. The BeGraft Stent Graft was used outside its initial intention for use as a bridging stent graft (BSG) for FEVAR. Primary endpoints were technical success, BSG patency, and absence of procedure related complications and BSG related endoleaks at 12 months.</p><p><strong>Results: </strong>One hundred and three patients were prospectively enrolled. Three hundred and fifty BSGs were implanted as investigational devices and included in the analysis. Technical success was 98.3%. Two BSG occlusions were reported in the first 12 months. Primary patency at 12 months was 99.3%. The absence of procedure related complications was 88%. Freedom from BSG related endoleaks at 12 months was 99.6%. Freedom from BSG related re-interventions was 97%. Two device deficiencies occurred in two patients: one disconnection between the BSG and the balloon before deployment and one fracture of the BSG at one year. No migration > 10 mm of the BSG was recorded during the trial period.</p><p><strong>Conclusion: </strong>This study shows favourable short term outcomes of the BeGraft Stent Graft as a BSG in FEVAR with good primary patency and low rates of BSG related complications.</p>","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1016/j.ejvs.2026.01.055
Benjamin S Brooke, Gheorghe Doros, Maarit Venermo, Jeffrey J Siracuse, Ahmed M Abou-Zamzam, Hasan H Dosluoglu, Raghu L Motaganahalli, Matthew T Menard, Alik Farber, Michael S Conte
Objective: The Wound, Ischemia, and foot Infection (WIfI) staging system for chronic limb threatening ischaemia (CLTI) predicts outcomes after revascularisation, but individual components of WIfI have not been evaluated. This study was designed to evaluate changes in WIfI ischaemia grade as a predictor of major amputation after open and endovascular revascularisation in the Best Endovascular versus Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial.
Methods: A secondary analysis was conducted of patients with CLTI randomised to surgical bypass or endovascular therapy as part of the BEST-CLI trial with available WIfI ischaemia scores at baseline and 1 month post-procedure. Risk adjusted Cox regression models were used to assess the effect of change in WIfI ischaemia grade on the rate of major amputation, while controlling for potential confounders.
Results: Among 785 patients with CLTI who underwent revascularisation and were alive at 1 year, 629 (80.1%) achieved improvement in their WIfI ischaemia grade within 30 days after undergoing surgical and endovascular interventions. Patients with improved ischaemia grade were younger and were more likely to smoke, have lower baseline ankle brachial indices, and have worse overall WIfI stage at time of revascularisation compared with patients with worsening or no improvement in limb perfusion (p < .050 for all comparisons). Major amputation incidence at 1 year was 14% and was increased among those with higher baseline WIfI stage (3/4 vs. 1/2) and with unchanged or worse WIfI ischaemia grade after revascularisation. Patients with improved WIfI ischaemia grade early after revascularisation had a statistically significantly lower likelihood of major amputation at 1 year (hazard ratio 0.27, 95% confidence interval 0.18 - 0.41; p < .001) after risk adjustment.
Conclusion: Achieving early improvement in limb perfusion based on WIfI ischaemia grade predicts major amputation following revascularisation independent of other risk factors. Changes in ischaemia grade after interventions should be closely monitored to determine the adequacy of revascularisation, risk of CLTI progression, and need for major amputation.
{"title":"Early Improvement in Wound, Ischemia, and foot Infection (WIfI) Ischaemia Grade Lowers Risk for Major Amputation following Revascularisation for Chronic Limb Threatening Ischaemia.","authors":"Benjamin S Brooke, Gheorghe Doros, Maarit Venermo, Jeffrey J Siracuse, Ahmed M Abou-Zamzam, Hasan H Dosluoglu, Raghu L Motaganahalli, Matthew T Menard, Alik Farber, Michael S Conte","doi":"10.1016/j.ejvs.2026.01.055","DOIUrl":"https://doi.org/10.1016/j.ejvs.2026.01.055","url":null,"abstract":"<p><strong>Objective: </strong>The Wound, Ischemia, and foot Infection (WIfI) staging system for chronic limb threatening ischaemia (CLTI) predicts outcomes after revascularisation, but individual components of WIfI have not been evaluated. This study was designed to evaluate changes in WIfI ischaemia grade as a predictor of major amputation after open and endovascular revascularisation in the Best Endovascular versus Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial.</p><p><strong>Methods: </strong>A secondary analysis was conducted of patients with CLTI randomised to surgical bypass or endovascular therapy as part of the BEST-CLI trial with available WIfI ischaemia scores at baseline and 1 month post-procedure. Risk adjusted Cox regression models were used to assess the effect of change in WIfI ischaemia grade on the rate of major amputation, while controlling for potential confounders.</p><p><strong>Results: </strong>Among 785 patients with CLTI who underwent revascularisation and were alive at 1 year, 629 (80.1%) achieved improvement in their WIfI ischaemia grade within 30 days after undergoing surgical and endovascular interventions. Patients with improved ischaemia grade were younger and were more likely to smoke, have lower baseline ankle brachial indices, and have worse overall WIfI stage at time of revascularisation compared with patients with worsening or no improvement in limb perfusion (p < .050 for all comparisons). Major amputation incidence at 1 year was 14% and was increased among those with higher baseline WIfI stage (3/4 vs. 1/2) and with unchanged or worse WIfI ischaemia grade after revascularisation. Patients with improved WIfI ischaemia grade early after revascularisation had a statistically significantly lower likelihood of major amputation at 1 year (hazard ratio 0.27, 95% confidence interval 0.18 - 0.41; p < .001) after risk adjustment.</p><p><strong>Conclusion: </strong>Achieving early improvement in limb perfusion based on WIfI ischaemia grade predicts major amputation following revascularisation independent of other risk factors. Changes in ischaemia grade after interventions should be closely monitored to determine the adequacy of revascularisation, risk of CLTI progression, and need for major amputation.</p>","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.ejvs.2025.12.038
Shinji Miyamoto, Ramon L Varcoe
{"title":"Reflections on the 2026 European Society for Vascular Surgery (ESVS) Guidelines for Descending Thoracic and Thoraco-abdominal Aortic Diseases: The Japanese and Australian Perspectives.","authors":"Shinji Miyamoto, Ramon L Varcoe","doi":"10.1016/j.ejvs.2025.12.038","DOIUrl":"https://doi.org/10.1016/j.ejvs.2025.12.038","url":null,"abstract":"","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":"71 2","pages":"170-171"},"PeriodicalIF":6.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.ejvs.2025.12.054
Matthew P Sweet, Sara L Zettervall
{"title":"European Society for Vascular Surgery 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases: a North American Perspective.","authors":"Matthew P Sweet, Sara L Zettervall","doi":"10.1016/j.ejvs.2025.12.054","DOIUrl":"https://doi.org/10.1016/j.ejvs.2025.12.054","url":null,"abstract":"","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":"71 2","pages":"167-169"},"PeriodicalIF":6.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.ejvs.2025.12.043
Bijan Modarai, Luca Bertoglio, Dittmar Böckler
{"title":"Advancing Aortic Care: The 2026 European Society for Vascular Surgery (ESVS) Guidelines on Descending Thoracic and Thoraco-abdominal Disease.","authors":"Bijan Modarai, Luca Bertoglio, Dittmar Böckler","doi":"10.1016/j.ejvs.2025.12.043","DOIUrl":"https://doi.org/10.1016/j.ejvs.2025.12.043","url":null,"abstract":"","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":"71 2","pages":"165-166"},"PeriodicalIF":6.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.ejvs.2026.01.056
Tasnuva Rahman, Katariina Noronen, Sari M Vähäaho, Karoliina Halmesmäki, Maarit Venermo
Objective: To compare high ligation and stripping (HLS), endovenous laser ablation (EVLA), and ultrasound guided foam sclerotherapy (UGFS) for symptomatic great saphenous vein (GSV) reflux in the long term, given the limited comparative data beyond ten years.
Methods: Patients with symptomatic GSV reflux were randomised (1:1:1) to undergo HLS, EVLA, or UGFS. One hundred and ninety-six patients treated at Helsinki University Hospital were invited to 14 year follow up. Primary outcomes were above knee GSV reflux and GSV re-intervention rates. Secondary outcomes included quality of life.
Results: Of 233 randomised patients, 214 were included. UGFS increased the risk of GSV reflux recurrence compared with both HLS (risk ratio [RR] 11.7, 95% confidence interval [CI] 1.6 - 85.6) and EVLA (RR 5.0, 95% CI 1.5 - 16.6; 30.8% [12 of 39] after UGFS vs. 2.6% [1 of 38] and 6.1% [3 of 49] after HLS and EVLA, respectively; overall p < .001). UGFS was associated with a higher risk of GSV re-interventions compared with HLS (RR 4.3, 95% CI 1.8 - 10.2) and EVLA (RR 6.9, 95% CI 2.6 - 18.4; 56.4% for UGFS vs. 13.2% for HLS and 8.2% for EVLA; overall p < .001). Neovascularisation rates did not differ between the treatments (29.0%, 22.5%, and 23.1% for HLS, EVLA, and UGFS, respectively; overall p = .76). Aberdeen Varicose Vein Questionnaire scores were comparable across the groups (median [interquartile range] 8.9 [3.7, 13.3] in HLS, 6.1 [0.8, 12.2] in EVLA, and 8.8 [4.1, 13.4] in UGFS, with median differences of +2.8 [HLS vs. EVLA], +0.1 [HLS vs. UGFS], and -2.7 [EVLA vs. UGFS]; overall p = .21).
Conclusion: UGFS demonstrated inferior outcomes in terms of GSV recurrent reflux and re-intervention rates compared with both HLS and EVLA, whereas HLS and EVLA showed comparable performance across these outcomes. Long term quality of life was comparable across all groups.
目的:比较高位结扎剥脱(HLS)、静脉内激光消融(EVLA)和超声引导泡沫硬化治疗(UGFS)治疗症状性大隐静脉(GSV)反流的长期疗效,因为10年以上的比较数据有限。方法:有症状的GSV反流患者随机(1:1:1)接受HLS、EVLA或UGFS。在赫尔辛基大学医院接受治疗的196名患者被邀请进行了14年的随访。主要结局是膝关节以上GSV反流和GSV再干预率。次要结果包括生活质量。结果:在233例随机患者中,214例纳入研究。与HLS和EVLA相比,UGFS增加了GSV反流复发的风险(风险比[RR] 11.7, 95%可信区间[CI] 1.6 - 85.6)和EVLA (RR 5.0, 95% CI 1.5 - 16.6; UGFS组30.8% [39 / 12],HLS和EVLA组分别为2.6%[38 / 1]和6.1%[49 / 3],总p < .001)。与HLS (RR 4.3, 95% CI 1.8 - 10.2)和EVLA (RR 6.9, 95% CI 2.6 - 18.4; UGFS为56.4%,HLS为13.2%,EVLA为8.2%,总体p < 0.001)相比,UGFS与GSV再干预的风险更高。新血管成形率在处理之间没有差异(HLS, EVLA和UGFS分别为29.0%,22.5%和23.1%;总体p = 0.76)。阿伯丁静脉曲张问卷评分在各组间具有可比性(HLS组中位数为8.9 [3.7,13.3],EVLA组中位数为6.1 [0.8,12.2],UGFS组中位数为8.8[4.1,13.4],中位数差异为+2.8 [HLS vs. EVLA], +0.1 [HLS vs. UGFS], -2.7 [EVLA vs. UGFS],总p = 0.21)。结论:与HLS和EVLA相比,UGFS在GSV复发性反流和再干预率方面表现较差,而HLS和EVLA在这些结果方面表现相当。所有组的长期生活质量具有可比性。
{"title":"Fourteen Year Outcomes of a Randomised Controlled Trial Comparing Endovenous Laser Ablation, High Ligation and Stripping, and Ultrasound Guided Foam Sclerotherapy for Great Saphenous Varicose Veins.","authors":"Tasnuva Rahman, Katariina Noronen, Sari M Vähäaho, Karoliina Halmesmäki, Maarit Venermo","doi":"10.1016/j.ejvs.2026.01.056","DOIUrl":"https://doi.org/10.1016/j.ejvs.2026.01.056","url":null,"abstract":"<p><strong>Objective: </strong>To compare high ligation and stripping (HLS), endovenous laser ablation (EVLA), and ultrasound guided foam sclerotherapy (UGFS) for symptomatic great saphenous vein (GSV) reflux in the long term, given the limited comparative data beyond ten years.</p><p><strong>Methods: </strong>Patients with symptomatic GSV reflux were randomised (1:1:1) to undergo HLS, EVLA, or UGFS. One hundred and ninety-six patients treated at Helsinki University Hospital were invited to 14 year follow up. Primary outcomes were above knee GSV reflux and GSV re-intervention rates. Secondary outcomes included quality of life.</p><p><strong>Results: </strong>Of 233 randomised patients, 214 were included. UGFS increased the risk of GSV reflux recurrence compared with both HLS (risk ratio [RR] 11.7, 95% confidence interval [CI] 1.6 - 85.6) and EVLA (RR 5.0, 95% CI 1.5 - 16.6; 30.8% [12 of 39] after UGFS vs. 2.6% [1 of 38] and 6.1% [3 of 49] after HLS and EVLA, respectively; overall p < .001). UGFS was associated with a higher risk of GSV re-interventions compared with HLS (RR 4.3, 95% CI 1.8 - 10.2) and EVLA (RR 6.9, 95% CI 2.6 - 18.4; 56.4% for UGFS vs. 13.2% for HLS and 8.2% for EVLA; overall p < .001). Neovascularisation rates did not differ between the treatments (29.0%, 22.5%, and 23.1% for HLS, EVLA, and UGFS, respectively; overall p = .76). Aberdeen Varicose Vein Questionnaire scores were comparable across the groups (median [interquartile range] 8.9 [3.7, 13.3] in HLS, 6.1 [0.8, 12.2] in EVLA, and 8.8 [4.1, 13.4] in UGFS, with median differences of +2.8 [HLS vs. EVLA], +0.1 [HLS vs. UGFS], and -2.7 [EVLA vs. UGFS]; overall p = .21).</p><p><strong>Conclusion: </strong>UGFS demonstrated inferior outcomes in terms of GSV recurrent reflux and re-intervention rates compared with both HLS and EVLA, whereas HLS and EVLA showed comparable performance across these outcomes. Long term quality of life was comparable across all groups.</p>","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-31DOI: 10.1016/j.ejvs.2026.01.052
Salvatore T Scali, Adam W Beck
{"title":"Survival Is No Longer Enough: Rethinking Quality in Complex Aortic Surgery.","authors":"Salvatore T Scali, Adam W Beck","doi":"10.1016/j.ejvs.2026.01.052","DOIUrl":"https://doi.org/10.1016/j.ejvs.2026.01.052","url":null,"abstract":"","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1016/j.ejvs.2026.01.048
Martin Altreuther, Arne Seternes
{"title":"Don't Forget the Heart: Surgical Excellence Alone Is Not Enough.","authors":"Martin Altreuther, Arne Seternes","doi":"10.1016/j.ejvs.2026.01.048","DOIUrl":"https://doi.org/10.1016/j.ejvs.2026.01.048","url":null,"abstract":"","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1016/j.ejvs.2026.01.054
Morgan T McLoughlin, Gergely Gosi
{"title":"Life Expectancy in Abdominal Aortic Aneurysm: A Need for a Validated Prognostic Score.","authors":"Morgan T McLoughlin, Gergely Gosi","doi":"10.1016/j.ejvs.2026.01.054","DOIUrl":"https://doi.org/10.1016/j.ejvs.2026.01.054","url":null,"abstract":"","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1016/j.ejvs.2026.01.050
Binshan Zha, Zhiyong Chen
{"title":"Fibromuscular Dysplasia of the Brachial Artery: An Incidental Finding during Mechanical Rotational Thrombectomy.","authors":"Binshan Zha, Zhiyong Chen","doi":"10.1016/j.ejvs.2026.01.050","DOIUrl":"https://doi.org/10.1016/j.ejvs.2026.01.050","url":null,"abstract":"","PeriodicalId":55160,"journal":{"name":"European Journal of Vascular and Endovascular Surgery","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}